Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Yao Chen, Xuejiao Qie, Wei Quan, Maomao Zeng, Fang Qin, Jie Chen, Benu Adhikari & Zhiyong He. (2023) Omnifarious fruit polyphenols: an omnipotent strategy to prevent and intervene diabetes and related complication?. Critical Reviews in Food Science and Nutrition 63:20, pages 4288-4324.
Read now
Read now
Harmanjit Singh, Jasbir Singh, Ravneet Kaur Bhangu, Mandeep Singla, Jagjit Singh & Farideh Javid. (2023) Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects. Expert Review of Clinical Pharmacology 16:1, pages 49-59.
Read now
Read now
Ashwani Sharma, Tarun Virmani, Anjali Sharma, Vaishnavi Chhabra, Girish Kumar, Kamla Pathak & Abdulsalam Alhalmi. (2022) Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes, Metabolic Syndrome and Obesity 15, pages 1845-1864.
Read now
Read now
Eugene Han, Minyoung Lee, Yong-ho Lee, Hye Soon Kim, Byung-wan Lee, Bong-Soo Cha & Eun Seok Kang. (2020) Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity 13, pages 4113-4121.
Read now
Read now
S Erande, S Sarwardekar & B Desai. (2019)
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the “thorough QT/QTc” study (Q-SET study). Diabetes, Metabolic Syndrome and Obesity 12, pages 961-967.
Read now
Read now
Sohan S. Chitlange, Diptee G. Rawat & Sejal P. Gandhi. (2017) Estimation of Anti Diabetic Teneligliptin in Bulk and Formulation by Densitometric and Spectrophotometric Method. Analytical Chemistry Letters 7:4, pages 556-566.
Read now
Read now
Yoshinori Okuda, Seitaro Omoto, Takehito Taniura, Akira Shouzu & Shosaku Nomura. (2016) Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis. International Journal of General Medicine 9, pages 65-71.
Read now
Read now
Surendra Kumar Sharma, A Panneerselvam, KP Singh, Girish Parmar, Pradeep Gadge & Onkar C Swami. (2016) Teneligliptin in management of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 9, pages 251-260.
Read now
Read now
Shuji Kinoshita & Kazuoki Kondo. (2015) Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opinion on Drug Metabolism & Toxicology 11:1, pages 7-14.
Read now
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Read now
Dilip C. Kanjariya, Hem N. Naik, Meet J. Sherashiya, Yogesh T. Naliapara, Iqrar Ahmad, Harun Patel, Dhanji Rajani & Smita Jauhari. α-Amylase and mycobacterium-TB H37Rv antagonistic efficacy of novel pyrazole-coumarin hybrids: an in vitro and in silico investigation. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-18.
Read now
Read now
Articles from other publishers (58)
Sara Nabil Shabaan, Fawzia Saleh Alshehri, Jinan Fadel AL‐Rasheed, Samiha A. El‐Sebaey & Ebtehal M. Husseiny. (2023)
Synthesis and Exploration of New Imidazo[4,5‐c]Pyrazoles as Potent
α
‐Amylase Inhibitors
. ChemistrySelect 8:14.
Crossref
Crossref
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li & Nigel H. Greig. (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacological Research 186, pages 106550.
Crossref
Crossref
Hongliang Li, Jin Ryeol An, Minju Park, Jaehee Choi, Ryeon Heo, Minji Kang, Seo-Yeong Mun, Wenwen Zhuang, Mi Seon Seo, Eun-Taek Han, Jin-Hee Han, Wanjoo Chun & Won Sun Park. (2022) The antidiabetic drug teneligliptin induces vasodilation via activation of PKG, Kv channels, and SERCA pumps in aortic smooth muscle. European Journal of Pharmacology 935, pages 175305.
Crossref
Crossref
Rajmohan Seetharaman, Sudhir Pawar & Manjari Advani. (2021) One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. British Journal of Clinical Pharmacology 88:4, pages 1598-1612.
Crossref
Crossref
Kumaravelrajan R, Thirumaran M, Sangavi T & Suba V. (2022) PREPARATION AND EVALUATION OF ACTIVE FILM COATING TABLET OF TENELIGLIPTIN HYDROBROMIDE HYDRATE WITH METFORMIN HYDROCHLORIDE FIXED DOSE COMBINATION. INDIAN DRUGS 58:12, pages 22-31.
Crossref
Crossref
Banshi Saboo, Suhas Erande & A.G. Unnikrishnan. (2022) A prospective multicentre open label study to assess effect of Teneligliptin on glycemic control through parameters of time in range (TIR) Metric using continuous glucose monitoring (TOP-TIR study). Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:2, pages 102394.
Crossref
Crossref
Takahiro Mori, Tomohisa Nagata, Masako Nagata, Kenji Fujimoto, Yoshihisa Fujino & Koji Mori. (2021) Diabetes severity measured by treatment control status and number of anti-diabetic drugs affects presenteeism among workers with type 2 diabetes. BMC Public Health 21:1.
Crossref
Crossref
Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyung Wan Min, Eun Jung Kyung, Yeo Kyeong Kim & Kwan Woo Lee. (2021) Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study. Diabetes Therapy 12:11, pages 2907-2920.
Crossref
Crossref
Banshi Saboo, Sujoy Ghosh, Mangesh Tiwaskar & Rajeev Chawla. (2021) QTc prolongation Safety and Effectiveness of Teneligliptin in Indian patients with type 2 Diabetes Mellitus: A real world study (QSET 2). Diabetes & Metabolic Syndrome: Clinical Research & Reviews 15:5, pages 102264.
Crossref
Crossref
Kalyani FarkadeMukund Tawar. (2021) Analytical Method Validation and Quantitative Analysis for Active Pharmaceutical Ingredient and Marketed Formulation of Teneligliptin Hydrobromide by UV Spectroscopy. Asian Journal of Pharmaceutical Analysis, pages 195-198.
Crossref
Crossref
Linong Ji, Jianhua Ma, Weiping Lu, Jingdong Liu, Jiao’e Zeng, Jialin Yang, Wei Li, Xiuzhen Zhang, Xinhua Xiao, Gen Takayanagi & Yi Wang. (2020) Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Journal of Diabetes Investigation 12:4, pages 537-545.
Crossref
Crossref
Ashit Syngle, Simran Chahal & Kanchan Vohra. (2020) Efficacy and tolerability of DPP4 inhibitor, teneligliptin, on autonomic and peripheral neuropathy in type 2 diabetes: an open label, pilot study. Neurological Sciences 42:4, pages 1429-1436.
Crossref
Crossref
Linong Ji, Ling Li, Jianhua Ma, Xuefeng Li, Dongmei Li, Bangzhu Meng, Weiping Lu, Jiao Sun, Yanmei Liu, Gen Takayanagi & Yi Wang. (2021) Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study. Endocrinology, Diabetes & Metabolism 4:2.
Crossref
Crossref
Mrityunjay Kumar PanditDr.Dr., Iftekhar AhmadDr.Dr., Jeetendra KumarDr.Dr. & Debarshi JanaDr.Dr.. (2020) COMPARISON OF EFFICACY AND SAFETY OF TENELIGLIPTIN VERSUS SITAGLIPTIN AS ADD ON TO METFORMIN IN TYPE 2 DIABETES MELLITUS AT JLNMC, BHAGALPUR, BIHAR. INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH, pages 42-44.
Crossref
Crossref
Sujoy Ghosh, Mangesh Tiwaskar, Rajiv Chawla, Shalini Jaggi, Arthur Asirvatham & Vijay Panikar. (2020) Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2). Diabetes Therapy 11:10, pages 2257-2268.
Crossref
Crossref
Amrish Chandra, Ramji Rathod, Faraat Ali, Anuj Prakash, Robin Kumar & Gyanendra Nath Singh. (2020) Development and Validation of a Rapid and Sensitive Method for the Simultaneous Estimation of Gemigliptin and Teneligliptin in Bulk and Dosage Forms by Using Liquid Chromatography-tandem Mass Spectrometry. Current Pharmaceutical Analysis 16:8, pages 1104-1111.
Crossref
Crossref
Shrikrishna V. Acharya. (2020) Is Teneligliptin Safe in Patients with Diabetes Mellitus Mainly with Reference to QT Prolongation. Journal of Evolution of Medical and Dental Sciences 9:31, pages 2171-2175.
Crossref
Crossref
Lei Zhang, Weiqiong Yuan, Xiangli Kong & Bei Zhang. (2020)
Teneligliptin protects against ischemia/reperfusion-induced endothelial permeability
in vivo
and
in vitro
. RSC Advances 10:7, pages 3765-3774.
Crossref
Crossref
Rajeev Chawla, SV Madhu, BM Makkar, Sujoy Ghosh, Banshi Saboo & Sanjay Kalra. (2020) RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism 24:1, pages 1.
Crossref
Crossref
Shruti Surendran, Rekha Sapkal, David Paul & Satheeshkumar Nanjappan. (2020) Effect of resveratrol on dipeptidyl peptidase-4 inhibitors pharmacokinetics: An in vitro and in vivo approach. Chemico-Biological Interactions 315, pages 108909.
Crossref
Crossref
Xiaoyan Deng, Na Wang, Liuwei Meng, Siru Zhou, Junli Huang, Junhao Xing, Linhong He, Weizhe Jiang & Qing Li. (2020) Optimization of the benzamide fragment targeting the S2′ site leads to potent dipeptidyl peptidase-IV inhibitors. Bioorganic Chemistry 94, pages 103366.
Crossref
Crossref
Rajeev Chawla, S. V. Madhu, B. M. Makkar, Sujoy Ghosh, Banshi Saboo & Sanjay Kalra. (2020) RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. International Journal of Diabetes in Developing Countries 40:S1, pages 1-122.
Crossref
Crossref
Jin‐Woo Park, Kyoung‐Ah Kim, Yun Jung Choi, Soo Hyun Yoon & Ji‐Young Park. (2019) Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. Journal of Clinical Pharmacy and Therapeutics 44:5, pages 720-725.
Crossref
Crossref
Krisyanti Budipramana, Junaidin Junaidin, Komar Ruslan Wirasutisna, Yanatra Budi Pramana & Sukrasno Sukrasno. (2019) An Integrated In Silico and In Vitro Assays of Dipeptidyl Peptidase-4 and α-Glucosidase Inhibition by Stellasterol from Ganoderma australe. Scientia Pharmaceutica 87:3, pages 21.
Crossref
Crossref
Munehiro Kitada, Yoshio Ogura, Kyoko Nitta, Mizue Fujii, Keizo Kanasaki, Kazunori Konishi, Yasuo Iida, Atsushi Nakagawa & Daisuke Koya. (2018) Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease. Journal of Diabetes Investigation 10:3, pages 706-713.
Crossref
Crossref
Naina Mohamed Pakkir Maideen. (2019) Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump. World Journal of Meta-Analysis 7:4, pages 156-161.
Crossref
Crossref
Elliot J. Glotfelty, Thomas E. Delgado, Luis B. Tovar-y-Romo, Yu Luo, Barry J. Hoffer, Lars Olson, Tobias E. Karlsson, Mark P. Mattson, Brandon K. Harvey, David Tweedie, Yazhou Li & Nigel H. Greig. (2019) Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury. ACS Pharmacology & Translational Science 2:2, pages 66-91.
Crossref
Crossref
Amankeldi A. Salybekov, Haruchika Masuda, Kozo Miyazaki, Yin Sheng, Atsuko Sato, Tomoko Shizuno, Yumi Iida, Yoshinori Okada & Takayuki Asahara. (2019) Dipeptidyl dipeptidase-4 inhibitor recovered ischemia through an increase in vasculogenic endothelial progenitor cells and regeneration-associated cells in diet-induced obese mice. PLOS ONE 14:3, pages e0205477.
Crossref
Crossref
Yonghyun Kim, Eun Seok Kang, Hak Chul Jang, Dong Jun Kim, Taekeun Oh, Eun Sook Kim, Nan-Hee Kim, Kyung Mook Choi, Sung-Rae Kim, JiYoung You, Se-Jin Kim & Moon-Kyu Lee. (2019) Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism 21:3, pages 631-639.
Crossref
Crossref
Takashi Kadowaki, Nobuaki Sarai, Takeshi Hirakawa, Kentaro Taki, Kosuke Iwasaki & Hisashi Urushihara. (2018) Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis. Diabetes, Obesity and Metabolism 20:12, pages 2830-2839.
Crossref
Crossref
Xiaoxuan Li, Xuefei Huang, Chongfei Bai, Dalian Qin, Shousong Cao, Qibing Mei, Yun Ye & Jianming Wu. (2018) Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 9.
Crossref
Crossref
Gulmira Turdu, Hongwei Gao, Yingying Jiang & Madina Kabas. (2018) Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review. Future Medicinal Chemistry 10:10, pages 1229-1239.
Crossref
Crossref
P Mandal, S Dan, B. Ghosh, S. Barma, R. Bose & T. K Pal. (2018) SIMULTANEOUS DETERMINATION AND QUANTITATION OF METFORMIN AND TENELIGLIPTIN IN HUMAN PLASMA BY LC-ESI-MS/MS WITH AN APPLICATION TO PHARMACOKINETIC STUDIES. INDIAN DRUGS 55:04, pages 28-38.
Crossref
Crossref
Priyanka A Shah, Pranav S Shrivastav, Pravin G Vanol & Mallika Sanyal. (2018) Mechanistic study for the simultaneous determination of metformin and teneligliptin in human plasma using hydrophilic interaction liquid chromatography–MS/MS. Bioanalysis 10:7, pages 475-488.
Crossref
Crossref
P. B. Deshpande & S. R. Butle. (2018) Determination of Dipeptidyl Peptidase-4 Inhibitors by Spectrophotometric and Chromatographic Methods. Journal of Analytical Chemistry 73:4, pages 303-316.
Crossref
Crossref
Piyush Agarwal, Chhavi Jindal & Vinayak Sapakal. (2018) Efficacy and safety of teneligliptin in Indian patients with inadequately controlled Type 2 diabetes mellitus: A randomized, double-blind study. Indian Journal of Endocrinology and Metabolism 22:1, pages 41.
Crossref
Crossref
Neeraj Kumar, Subba Rao Devineni, Kadirappa Aggile, Prasad Reddy Gajjala, Pramod Kumar & Shailendra Kumar Dubey. (2017) Facile new industrial process for synthesis of teneligliptin through new intermediates and its optimization with control of impurities. Research on Chemical Intermediates 44:1, pages 567-584.
Crossref
Crossref
Chintan N. Koyani, Ewald Kolesnik, Gerald Wölkart, Niroj Shrestha, Susanne Scheruebel, Christopher Trummer, Klaus Zorn-Pauly, Astrid Hammer, Petra Lang, Helga Reicher, Heinrich Maechler, Klaus Groschner, Bernd Mayer, Peter P. Rainer, Harald Sourij, Wolfgang Sattler, Ernst Malle, Brigitte Pelzmann & Dirk von Lewinski. (2017) Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure. Biochemical Pharmacology 145, pages 64-80.
Crossref
Crossref
Takashi Kadowaki, Nobuya Inagaki, Kazuoki Kondo, Kenichi Nishimura, Genki Kaneko, Nobuko Maruyama, Nobuhiro Nakanishi, Hiroaki Iijima, Yumi Watanabe & Maki Gouda. (2017) Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism 19:6, pages 874-882.
Crossref
Crossref
AwadheshKumar Singh. (2017) Efficacy and safety of teneligliptin. Indian Journal of Endocrinology and Metabolism 21:1, pages 11.
Crossref
Crossref
Ahsan Sajjad. (2017) Comparison of Efficacy and Safety of Hydroxychloroquine and Teneligliptin in Type 2 Diabetes Patients who are Inadequately Controlled with Glimepiride, Metformin and Insulin therapy: A Randomized Controlled Trial with Parallel Group Design. Annals of Clinical Endocrinology and Metabolism 2:1, pages 033-040.
Crossref
Crossref
T. N. V. Ganesh Kumar, S. Vidyadhara, Niteen Ashok Narkhede, Y. Sai Silpa & M. Rajya Lakshmi. (2016) Method development, validation, and stability studies of teneligliptin by RP-HPLC and identification of degradation products by UPLC tandem mass spectroscopy. Journal of Analytical Science and Technology 7:1.
Crossref
Crossref
T. N. V. Ganesh Kumar, S. Vidyadhara, Niteen Ashok Narkhede, Y. Sai Silpa & M. Rajya Lakshmi. (2016) RETRACTED ARTICLE: Method development, validation, and stability studies of teneligliptin by RP-HPLC and identification of degradation products by UPLC tandem mass spectroscopy. Journal of Analytical Science and Technology 7:1.
Crossref
Crossref
P. Sneha & C. George Priya Doss. (2016) Gliptins in managing diabetes - Reviewing computational strategy. Life Sciences 166, pages 108-120.
Crossref
Crossref
Eiji Kutoh, Asuka Wada & Sayaka Terayama. (2016) Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties. Clinical Drug Investigation 36:10, pages 809-818.
Crossref
Crossref
Manish Maladkar, Srividya Sankar & Kushal Kamat. (2016) Teneligliptin: Heralding Change in Type 2 Diabetes. Journal of Diabetes Mellitus 06:02, pages 113-131.
Crossref
Crossref
Enrique Z. Fisman & Alexander Tenenbaum. (2015) Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Noritsugu Wada, Katsuhito Mori, Chie Nakagawa, Jun Sawa, Yasuro Kumeda, Tetsuo Shoji, Masanori Emoto & Masaaki Inaba. (2015) Improved glycemic control with teneligliptin in patients with type 2 diabetes mellitus on hemodialysis: Evaluation by continuous glucose monitoring. Journal of Diabetes and its Complications 29:8, pages 1310-1313.
Crossref
Crossref
Lesley J. Scott. (2015) Teneligliptin: A Review in Type 2 Diabetes. Clinical Drug Investigation 35:11, pages 765-772.
Crossref
Crossref
Yuji Kumagai, Tomoko Hasunuma, Soichi Sakai, Hidekazu Ochiai & Yoshishige Samukawa. (2015) Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects. PLOS ONE 10:10, pages e0139873.
Crossref
Crossref
Xiao-Wu Chen, Zhi-Xu He, Zhi-Wei Zhou, Tianxin Yang, Xueji Zhang, Yin-Xue Yang, Wei Duan & Shu-Feng Zhou. (2015) Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clinical and Experimental Pharmacology and Physiology 42:10, pages 999-1024.
Crossref
Crossref
Yuanyuan Gao, Yong Zhang, Jianming Zhu, Bo Li, Zhao Li, Weiliang Zhu, Jiye Shi, Qi Jia & Yiming Li. (2015) Recent progress in natural products as DPP-4 inhibitors. Future Medicinal Chemistry 7:8, pages 1079-1089.
Crossref
Crossref
Miyako Kishimoto & Mitsuhiko Noda. (2014) Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study. Clinical Drug Investigation 35:2, pages 141-147.
Crossref
Crossref
Kazunari Kamiko, Kazutaka Aoki, Hiroshi Kamiyama, Masataka Taguri, Eriko Shibata, Yumiko Ashiya, Fuyuki Minagawa, Kazuaki Shinoda, Shigeru Nakajima & Yasuo Terauchi. (2015) Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: A randomized non-inferior test. The Journal of Clinical Pharmacology 55:2, pages 144-151.
Crossref
Crossref
Atef Halabi, Haidar Maatouk, Karl Ernst Siegler, Nadja Faisst & Holger Hinrichsen. (2014) Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. Clinical Pharmacology in Drug Development 3:4, pages 290-296.
Crossref
Crossref
Bhumika D. Patel & Manjunath D. Ghate. (2014) Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. European Journal of Medicinal Chemistry 74, pages 574-605.
Crossref
Crossref
Hideo Otsuki, Takeo Kosaka, Kenzo Nakamura, Fumihiko Shimomura, Yoshitaka Kuwahara & Takuji Tsukamoto. (2013) Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes. International Urology and Nephrology 46:2, pages 427-432.
Crossref
Crossref
Hideo Otsuki, Kenzo Nakamura, Fumihiko Shimomura, Yoshitaka Kuwahara & Takuji Tsukamoto. (2014) Retraction: Efficacy of a novel DPP-4 inhibitor, teneligliptin, for hemodialysis patients with type 2 diabetes. Nihon Toseki Igakkai Zasshi 47:5, pages 299-303.
Crossref
Crossref